Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Small Cell Lung Carcinoma 2Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Oligodendroglioma 1Neoplasm Metastasis 1Malignant Solid Tumor 1Glioblastoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 29Bevacizumab 12Radiotherapy 10Irinotecan 7Carboplatin 7Carmustine 5Magnetic Resonance Spectroscopy 4Filgrastim 4Cyclophosphamide 4Cisplatin 4Vincristine 3Thiotepa 3Surgical Procedures, Operative 3Peripheral Blood Stem Cell Transplantation 3Etoposide 3talampanel 2sargramostim 2antineoplaston AS 2-1 2antineoplaston A10 2abemaciclib 2Topotecan 2Thalidomide 2Tamoxifen 2Sunitinib 2Radiotherapy, Intensity-Modulated 2Procarbazine 2Immunoglobulin G 2Everolimus 2Drug Therapy 2Doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Oligodendroglioma × etirinotecan pegol × Clear all
NCT01663012 2016-02-24

Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma

Stanford University

Phase 2 Completed
20 enrolled 10 charts
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡